Olema Pharmaceuticals’ (NASDAQ: OLMA stock) soared 197% in pre-market trading on Tuesday morning, despite no company announcements from Olema itself. The dramatic spike sent shockwaves through the biotech sector and caught traders off guard. The real story behind the surge? Swiss pharmaceutical giant Roche announced positive Phase III trial results for its competitor breast cancer











